A detailed history of Flagship Harbor Advisors, LLC transactions in Geron Corp stock. As of the latest transaction made, Flagship Harbor Advisors, LLC holds 27,122 shares of GERN stock, worth $110,115. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,122
Previous 26,203 3.51%
Holding current value
$110,115
Previous $86,000 43.02%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$4.17 - $4.99 $3,832 - $4,585
919 Added 3.51%
27,122 $123,000
Q1 2024

Apr 16, 2024

BUY
$1.75 - $3.44 $5,442 - $10,698
3,110 Added 13.47%
26,203 $86,000
Q4 2023

Jan 10, 2024

BUY
$1.74 - $2.31 $4,297 - $5,705
2,470 Added 11.98%
23,093 $48,000
Q3 2023

Oct 17, 2023

BUY
$2.11 - $3.28 $1,055 - $1,640
500 Added 2.48%
20,623 $43,000
Q2 2023

Jul 11, 2023

BUY
$1.97 - $3.69 $3,940 - $7,380
2,000 Added 11.04%
20,123 $64,000
Q1 2022

Apr 13, 2022

BUY
$0.99 - $1.6 $2,970 - $4,800
3,000 Added 19.84%
18,123 $25,000
Q4 2021

Feb 10, 2022

BUY
$1.22 - $1.72 $3,660 - $5,160
3,000 Added 24.75%
15,123 $18,000
Q1 2021

May 03, 2021

BUY
$1.52 - $2.1 $18,426 - $25,458
12,123 New
12,123 $19,000
Q4 2020

Feb 08, 2021

SELL
$1.55 - $2.05 $11,242 - $14,868
-7,253 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.27 - $1.54 $1,270 - $1,540
1,000 Added 15.99%
7,253 $10,000
Q1 2019

Apr 15, 2019

BUY
$1.01 - $1.83 $3,030 - $5,490
3,000 Added 92.22%
6,253 $10,000
Q4 2018

Jan 28, 2019

BUY
$0.98 - $1.85 $1,470 - $2,775
1,500 Added 85.57%
3,253 $3,000
Q2 2018

Aug 14, 2018

BUY
$3.29 - $4.82 $5,767 - $8,449
1,753 New
1,753 $6,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.53B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Flagship Harbor Advisors, LLC Portfolio

Follow Flagship Harbor Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.